As cancer immunotherapy continues to evolve, competition around therapeutic targets has expanded beyond single drug modalities to encompass a broad range of technology platforms. CD79b, a well-established therapeutic target for B-cell malignancies, exemplifies this transition. Initially validated through the clinical success of antibody-drug conjugates (ADCs), CD79b has since attracted increasing interest from multiple therapeutic modalities, including bispecific antibodies (BsAbs), T-cell engagers (TCEs), and cell-based therapies. As a result, CD79b is evolving from a mature ADC target into a comprehensive immunotherapy target with broad multimodal development potential.

About CD79b

CD79 is an essential component of the B-cell receptor (BCR) complex and consists of two distinct transmembrane proteins, CD79a (Igα) and CD79b (Igβ). These two chains are linked by disulfide bonds to form a heterodimer on the B-cell surface, where they associate with membrane-bound immunoglobulin (mIg) to constitute the functional BCR complex.

BCR signaling mediated by the CD79a/CD79b heterodimer activates a broad signaling network through the recruitment of spleen tyrosine kinase (Syk) and other downstream signaling molecules. This cascade subsequently triggers key pathways, including PI3K, BTK, and NF-κB, thereby regulating B-cell activation, proliferation, differentiation, and antibody production. Because of its central role in B-cell signaling, the CD79 complex is indispensable for the survival of both normal and malignant B cells.

CD79b is primarily expressed throughout B-cell development, from the pre-B-cell stage to mature B cells, with abundant expression in lymphoid tissues such as lymph nodes and the spleen. As a critical component of the BCR signaling machinery, CD79b plays an essential role in regulating B-cell signaling activity.

Studies have demonstrated that mutations in the CD79B gene can lead to constitutive activation of BCR signaling, contributing to the development and progression of various B-cell malignancies, particularly diffuse large B-cell lymphoma (DLBCL). Therefore, CD79b has emerged as an important therapeutic target for the treatment of B-cell lymphomas.

From Oncology to Autoimmunity

B-cell Malignancies

CD79b is highly expressed across multiple B-cell lymphoma subtypes, making it an important therapeutic target for B-cell lymphoma treatment. In certain B-cell lymphomas, genetic mutations or aberrant expression of CD79B can result in persistent activation of downstream signaling pathways, promoting abnormal B-cell proliferation and survival. This dysregulated signaling provides lymphoma cells with a growth advantage and enables them to evade normal apoptotic mechanisms.

Autoimmune Diseases

Beyond its role in BCR signal transduction, CD79b is also involved in regulating B-cell activation, proliferation, and survival, highlighting its potential as a therapeutic target in immune-mediated disorders. Therapeutic approaches targeting CD79b have been explored for the treatment of autoimmune diseases, including systemic lupus erythematosus (SLE), and have demonstrated potential in B-cell–directed therapeutic strategies.

ADC Leads the Field, While Multimodal Therapies Compete

To date, only one CD79b-targeted ADC has reached the market globally. Developed by Roche/Genentech, the CD79b ADC polatuzumab vedotin has been approved for the treatment of DLBCL and other indications.

Currently, CD79b drug development has expanded beyond the traditional ADC approach toward a diverse range of therapeutic modalities, including TCEs, BsAbs, and autologous CAR-T cell therapies. A global overview of key CD79b-targeted programs in development is shown below.

 ADC

ADCs represent the most mature and clinically validated modality in the CD79b field. The approval of polatuzumab vedotin (Polivy) demonstrated that CD79b is a viable therapeutic target for B-cell malignancies and provided the foundation for further development.

However, current CD79b ADC strategies are primarily focused on improving therapeutic efficacy and safety profiles, while the overall development landscape is gradually shifting toward immune-engaging approaches. As a validated target with established clinical proof-of-concept, CD79b continues to serve as an attractive antigen for next-generation ADC optimization.

Bispecific and TCE

Beyond ADCs, CD79b is increasingly being explored in bispecific and TCE platforms. Unlike ADCs that rely on intracellular payload delivery, these approaches aim to directly recruit immune effector cells and enhance anti-tumor immune responses.

By simultaneously targeting CD79b and immune activation molecules such as CD3, these next-generation antibodies have the potential to overcome some limitations of conventional antibody therapies, including tumor heterogeneity and insufficient immune activation. The advancement of CD79b-directed TCEs and multispecific antibodies highlights the transition of CD79b from a drug delivery antigen into an immune-modulating target.

CAR-T

CAR-T cell therapy represents another emerging strategy for CD79b targeting. By engineering patient-derived T cells to recognize CD79b-positive B-cell malignancies, this approach aims to leverage the potent and sustained cytotoxic activity of cellular immunotherapy.

Although CD79b CAR-T programs remain in early clinical development, they provide a potential alternative for patients with relapsed or refractory B-cell malignancies and further expand the therapeutic possibilities of CD79b beyond antibody-based approaches.

Conclusion

The development of CD79b-targeted therapies has evolved from an ADC-driven approach toward a diversified landscape encompassing ADCs, multispecific antibodies, T-cell engagers (TCEs), and cellular therapies. With continued advances in combination strategies and expansion into immunological indications, CD79b is expected to further unlock its therapeutic potential across B-cell malignancies and autoimmune diseases.

As CD79b-targeted therapies continue to expand across ADCs, bispecific antibodies, T-cell engagers, and cellular therapies, robust and reliable preclinical tools have become increasingly critical for target validation, drug screening, and functional evaluation.

To support the growing demand for CD79b-targeted drug development, Genomeditech has developed a series of CD79b stable overexpression cell lines. These rigorously validated cell models provide consistent and reliable performance across early-stage screening and preclinical research applications, helping accelerate the discovery and development of next-generation CD79b-targeted therapeutics.

Explore more: https://en.genomeditech.com/v2/search?k=CD79b 

References

1. Tkachenko A, Kupcova K, Havranek O. B-Cell Receptor Signaling and Beyond: The Role of Igα (CD79a)/Igβ (CD79b) in Normal and Malignant B Cells. International Journal of Molecular Sciences. 2023 Dec 19;25(1):10. doi:10.3390/ijms25010010. PMID:38203179; PMCID.

2. Huse K, Bai B, Hilden VI, Bollum LK, Våtsveen TK, Munthe LA, Smeland EB, Irish JM, Wälchli S, Myklebust JH. Mechanism of CD79A and CD79B Support for IgM+ B Cell Fitness through B Cell Receptor Surface Expression. The Journal of Immunology. 2022 Nov 15;209(10):2042-2053. doi:10.4049/jimmunol.2200144. PMID:36426942; PMCID.